USE OF 5% HUMAN ALBUMIN IN WASH AND HARVEST MEDIA
Provided herein are methods of harvesting NK-92® cells comprising collecting NK-92® cells from a cell culture and washing the collected NK-92® cells in a buffer comprising 1%-5% albumin.
1 . A method of harvesting NK-92® cells comprising collecting NK-92® cells from a cell culture and washing the collected NK-92® cells by resuspending the cells in a buffer comprising 1-5% albumin.
2 . The method of claim 1 , wherein the collecting NK-92® cells comprising centrifuging the NK-92® cells in the cell culture.
3 . The method of claim 1 , further comprising placing the washed NK-92® cells in an infusion bag.
4 . The method of claim 1 , wherein the wash is performed by centrifuging the cells and then resuspending the cells in the wash buffer.
5 . The method of claim 1 , wherein the wash is performed at least three times.
6 . The method of claim 1 , wherein the wash is performed 4-6 times.
7 . The method of claim 6 , wherein the method recovers at least 80% of the NK-92® cells.
8 . The method of claim 1 , wherein the viability of the harvested cells is at least 90%.
9 . The method of claim 1 , wherein the NK-92® cells that have been harvested have substantially the same cytotoxicity and/or viability as control NK-92® cells that have not been harvested.
10 . The method of claim 1 , wherein the NK-92® cells that have been harvested have substantially the same cytotoxicity and/or viability as the NK-92® cells before harvesting.
11 . The method of claim 1 , wherein the NK-92® cells that have been harvested have a cytotoxicity of 80-100% on K562 cells.
12 . The method of claim 1 , wherein the buffer contains 2-5% albumin.
13 . The method of claim 1 , wherein the buffer contains 3-5% albumin.
14 . The method of claim 1 , wherein the buffer contains 5% albumin.
15 . The method of claim 1 , wherein the buffer lacks sugar.
16 . The method of claim 1 , wherein the buffer lacks dextran.
17 . The method of claim 4 , wherein the centrifugation is by continuous centrifugation.
18 . The method of claim 1 , wherein the albumin is human albumin, or human serum derived albumin, or human plasma derived albumin.
19 . The method of claim 1 , wherein the NK-92® cells express a cytokine, Fc Receptor, a chimeric antigen receptor, or a combination thereof.
20 . The method of claim 19 , wherein the chimeric antigen receptor is a receptor for HER2, CD19 or PD-L1.
21 . The method of claim 19 , wherein the chimeric antigen receptor is a receptor for any of the tumor specific antigens listed in Table 1.